Teriparatide + Zoledronic Acid
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Osteoporosis, Post-menopausal
Conditions
Osteoporosis, Post-menopausal
Trial Timeline
Jul 1, 2009 โ Apr 1, 2012
NCT ID
NCT00927186About Teriparatide + Zoledronic Acid
Teriparatide + Zoledronic Acid is a approved stage product being developed by Eli Lilly for Osteoporosis, Post-menopausal. The current trial status is completed. This product is registered under clinical trial identifier NCT00927186. Target conditions include Osteoporosis, Post-menopausal.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00927186 | Approved | Completed |
| NCT01153425 | Approved | Completed |
Competing Products
20 competing products in Osteoporosis, Post-menopausal